Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (21-30 of 260) with videos related to

Pageof 26
Sort By:
JAMA Oncology|February 25, 2021
Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic AberrationsTimothy A Yap, Amber Johnson, Funda Meric-Bernstam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2024
PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLCNatalie I Vokes, Xiuning Le, Timothy A Yap
European Journal of Cancer (Oxford, England : 1990)|November 21, 2016
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancerTimothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
Journal of Hematology & Oncology|October 4, 2014
Strategies for modern biomarker and drug development in oncologyAlan D Smith, Desam Roda, Timothy A Yap
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and MisconceptionsFilip Janku, Kenneth R Hess, Timothy A Yap
Current Problems in Cancer|April 19, 2017
Circulating tumor DNA-From bench to bedsideJoline S J Lim, Filip Janku, Timothy A Yap
Expert Opinion on Pharmacotherapy|July 26, 2021
Development of the PARP inhibitor talazoparib for the treatment of advanced <i>BRCA1</i> and <i>BRCA2</i> mutated breast cancerEvthokia A Hobbs, Jennifer K Litton, Timothy A Yap
Expert Opinion on Drug Discovery|May 25, 2018
Challenges with biomarkers in cancer drug discovery and developmentEcaterina Ileana Dumbrava, Funda Meric-Bernstam, Timothy A Yap
Molecular Cancer Therapeutics|December 6, 2017
Precision Medicine: Progress, Pitfalls, and PromisesPatrick G Pilié, Patricia M LoRusso, Timothy A Yap
Annual Review of Medicine|October 13, 2021
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 BlockadeNatalie Y L Ngoi, Guang Peng, Timothy A Yap
Pageof 26

Showing results (21-30 of 260) with videos related to

Sort By:
Pageof 26
JAMA Oncology|February 25, 2021
Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic AberrationsTimothy A Yap, Amber Johnson, Funda Meric-Bernstam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2024
PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLCNatalie I Vokes, Xiuning Le, Timothy A Yap
European Journal of Cancer (Oxford, England : 1990)|November 21, 2016
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancerTimothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
Journal of Hematology & Oncology|October 4, 2014
Strategies for modern biomarker and drug development in oncologyAlan D Smith, Desam Roda, Timothy A Yap
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and MisconceptionsFilip Janku, Kenneth R Hess, Timothy A Yap
Current Problems in Cancer|April 19, 2017
Circulating tumor DNA-From bench to bedsideJoline S J Lim, Filip Janku, Timothy A Yap
Expert Opinion on Pharmacotherapy|July 26, 2021
Development of the PARP inhibitor talazoparib for the treatment of advanced <i>BRCA1</i> and <i>BRCA2</i> mutated breast cancerEvthokia A Hobbs, Jennifer K Litton, Timothy A Yap
Expert Opinion on Drug Discovery|May 25, 2018
Challenges with biomarkers in cancer drug discovery and developmentEcaterina Ileana Dumbrava, Funda Meric-Bernstam, Timothy A Yap
Molecular Cancer Therapeutics|December 6, 2017
Precision Medicine: Progress, Pitfalls, and PromisesPatrick G Pilié, Patricia M LoRusso, Timothy A Yap
Annual Review of Medicine|October 13, 2021
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 BlockadeNatalie Y L Ngoi, Guang Peng, Timothy A Yap
Pageof 26